Levofloxacin G+ aerobi Staphylococcus aureus S.

aureus (+) penicilinaz MRSA Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus pyogenes Streptococcus agalactiae Streptococcus viridans Mycobacterium Enterobacter aerogenes Enterobacter cloacae Escherichia coli Acinetobacter calcoaceticus Haemophilus influenzae Haemophilus parainfluenzae Klebsiella oxytoca Klebsiella pneumoniae Moraxella catarrhalis Morganella morganii Neisseria meningitidis Neisseria gonorrhoeae Proteus mirabilis Proteus vulgaris Enterococcus faecium Enterococcus faecalis Listeria monocytogenes Borrelia burgdorferi Serratia marcescens Providencia rettgeri Pseudomonas aeruginosa Salmonella typhi Salmonella spp. (non-typhoid) Shigella spp. Yersinia enterocolitica Brucella spp. Vibrio spp. Treponema pallidum Helicobacter pylori Campylobacter jejuni Bacteroides fragilis Fusobacterium * R * * * * * * * * * * * * * * * * * R* * * * * * G- aerobi

* * * * * * * * R *

R* R* * * * * * * * * * * * * R R R * R* * R * * * * * * *

Ceftriaxon * * R Methicillin-resistant Staphylococcus spp. are resistant to cephalosporins, including ceftriaxone. * * * * * R Emerging resistance to Levofloxacin Emerging resistance to Levofloxacin Emerging resistance to Levofloxacin Emerging resistance to Levofloxacin Recently resistant strains have been reported for the first time Strains reistant to levofloxacin have emerged in substantial numbers rapid se dezv. rezistenta la Levoflox.; Ceftriaxon are activitate slab vs Pseudomonas Ceftriaxone has been used as a reserved antibiotic for treatment of MDR Shigella spp. R Sensibilitate la Ceftriaxon sub 15% * 85% sensibil la Ceftriaxon R * * * * R R Ceftriaxone , like other cephalosporins, has no activity against Chlamydia trachomatis. R R

G- anaerobi

G+ anaerobi

Clostridium difficile Clostridium spp. (Excluzind "difficile") Peptostreptococcus sp. Peptococcus spp. Fusobacterium Chlamydia pneumoniae Chlamydia trachomatis Mycoplasma pneumoniae Legionella pneumophila

* *

Atipice

* * * *

Ciprofloxacin, enoxacin, lomefloxacin, levofloxacin, ofloxacin, and pefloxacin make up a second group of similar agents possessing excellent gram-negative activity and moderate to good activity against gram-positive bacteria. Levofloxacin, the L-isomer of ofloxacin, has superior activity against gram-positive organisms, including Streptococcus pneumoniae. Ciprofloxacin is the most active agent of this group against gram-negatives, Pseudomonas aeruginosa in particular. Other fluoroquinolones, in particular Ciprofloxacin (Cipro), are not sufficiently effective against Chlamydia species. Ciprofloxacin is more active than levofloxacin against P. aeruginosa. Levofloxacin is more active than ciprofloxacin against pneumococci, staphylococci, and Chlamydia. In general activity against anaerobic organisms is poor and levofloxacin should not be used to treat infections caused by anaerobes. Enterobacter, Serratia marcescens, and Citrobacter freundii tend to be resistant to ceftriaxone. Ceftriaxone is highly stable to most beta-lactamases, both penicillinases and cephalosporinases, of Gram-positive and Gram-negative bacteria. Levofloxacin, gatifloxacin, gemifloxacin, and moxifloxacin, so-called respiratory fluoroquinolones, with their enhanced gram-positive activity and activity against atypical pneumonia agents (eg, chlamydia, mycoplasma, and legionella), are effective and used increasingly for treatment of upper and lower respiratory tract infections. In MRSA isolates, a higher resistance rate was found for ciprofloxacin (95.7%) vs levofloxacin (82.1%) ( P = .04).